The Cooper Companies, Inc. with ticker code (COO) now have 12 confirmed analysts covering the stock with the consensus suggesting a rating of ‘buy’. The range between the high target price and low target price is between 440 and 343 calculating the average target price we see $404.33. Now with the previous closing price of $316.12 this now indicates there is a potential upside of 27.9%. The 50 day moving average now sits at $351.63 and the 200 day MA is $359.77. The company has a market cap of 15.39B. The stock price for the company is currently is currently 310.75 USD
The potential market cap would be $19,683,925,917 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 56.19, revenue per share of 71.07 and a 2.75% return on assets.
The Cooper Companies, Inc. is a global medical device company. The Company operates through two segments: CooperVision and CooperSurgical. CooperVision segment is engaged in developing, manufacturing and marketing a range of products for contact lens wearers, featuring advanced materials and optics. CooperVision segment designs its products to solve vision challenges, such as astigmatism, presbyopia, myopia, ocular dryness and eye fatigue, with a broad collection of spherical, toric and multifocal contact lenses. CooperSurgical segment focus on advancing the health of women, babies and families through a diversified portfolio of products and services focusing on women’s health and fertility. CooperSurgical segment supplies the family health care market with a diversified portfolio of products and services. Its office and surgical offerings include products that facilitate surgical and non-surgical procedures that are commonly performed primarily by obstetricians and gynecologists.